Intravenous Nitroglycerin Dosing Protocol
Start IV nitroglycerin at 5–10 µg/min using non-PVC tubing and titrate upward by 5–10 µg/min every 3–5 minutes until chest pain resolves or blood pressure targets are reached, while maintaining systolic BP ≥90 mmHg. 1, 2
Initial Setup and Starting Dose
- Use non-polyvinyl chloride (polyethylene) tubing to prevent drug adsorption into the infusion line, which can reduce delivered dose by up to 85% with standard PVC tubing 3, 4, 5
- Begin infusion at 5–10 µg/min for acute coronary syndrome or acute pulmonary edema 3, 1
- The FDA label specifies diluting to 50–100 µg/mL concentration (e.g., 50 mg in 500 mL yields 100 µg/mL) 4
- A 15 µg bolus may be given initially in select cases, though continuous infusion without bolus is the standard approach 3
Titration Strategy
For Acute Coronary Syndrome or Pulmonary Edema
- Increase by 5–10 µg/min every 3–5 minutes based on symptom relief (chest pain, dyspnea) and blood pressure response 3, 1, 6
- If no response at 20 µg/min, increase increments to 10 µg/min every 3–5 minutes 3, 6, 4
- At doses >50 µg/min, increments of 20 µg/min can be used if needed 6
- Usual maximum dose is 200 µg/min; doses beyond this increase hypotension risk and should prompt consideration of alternative vasodilators 3, 1, 6
For Hypertensive Emergencies (with ACS or APE only)
- Maximum dose is strictly limited to 20 µg/min in hypertensive emergencies 2
- Nitroglycerin is not first-line for hypertensive emergencies without concurrent ACS or pulmonary edema—use nicardipine or clevidipine instead 2
Blood Pressure Targets and Safety Limits
- Never allow systolic BP to fall below 90 mmHg or drop ≥30 mmHg from baseline 3, 1, 6, 4
- In previously normotensive patients, maintain systolic BP ≥110 mmHg 1, 6
- Limit BP reduction to ≤25% within the first hour of therapy to prevent organ hypoperfusion 3, 2
- In hypertensive patients, reduce mean arterial pressure by 10–30% from baseline 3, 6
Titration End Points
Stop increasing the dose when any of these occur:
- Complete relief of chest pain or dyspnea 3, 6
- Systolic BP approaches 90–110 mmHg (depending on baseline) 3, 1
- Heart rate increases >10 beats/min (but generally keep <110 bpm) 3
- Pulmonary capillary wedge pressure decreases by 10–30% (if monitored) 3
Absolute Contraindications
- Systolic BP <90 mmHg or ≥30 mmHg drop from baseline 3, 1, 6
- Phosphodiesterase-5 inhibitor use within 24 hours (sildenafil, vardenafil) or 48 hours (tadalafil) due to risk of fatal hypotension 1, 2, 6
- Suspected right ventricular infarction—these patients are preload-dependent and can develop severe hypotension 1, 6
- Severe aortic stenosis—marked hypotension may occur 3
- Volume depletion—correct hypovolemia before initiating 3, 2
Monitoring Requirements
- Measure BP and heart rate every 3–5 minutes during initial titration 6
- Consider arterial line placement for doses >50–100 µg/min or in patients with borderline BP 3, 2
- Non-invasive BP monitoring is usually adequate at lower doses 3
Tolerance Development
- Tachyphylaxis begins after 7–8 hours and becomes clinically significant after 24 hours of continuous infusion 1, 2, 6
- Dose escalation may be required after 24–48 hours to maintain efficacy 3, 6
- When symptom-free for 12–24 hours, begin gradual wean and transition to oral or topical nitrates 2, 6
Critical Pitfalls to Avoid
- Do not use standard PVC tubing—up to 85% of drug can be absorbed, requiring much higher doses 3, 4, 5
- Do not exceed 20 µg/min in hypertensive emergencies unless treating refractory angina 2
- Do not use nitroglycerin as monotherapy—it must be part of comprehensive ACS management including antiplatelet agents and anticoagulation 1
- Do not drop BP >25% in the first hour, especially in elderly or chronically hypertensive patients 3, 2
- Always verify absence of recent PDE-5 inhibitor use before starting any nitrate 1, 2, 6
Adjunctive Therapy Considerations
- Add beta-blocker if reflex tachycardia develops to prevent increased myocardial oxygen demand 6
- Morphine 2–5 mg IV can be given for pain unresponsive to maximal anti-ischemic therapy, though it may delay oral P2Y12 inhibitor absorption 3, 1
- The combination of IV nitroglycerin with beta-blockers is well-tolerated and theoretically beneficial 3